Hotis, Peter D

Mr. Horn is a shareholder of the firm and focuses his practice on litigation involving prescription drug overcharges and commodities fraud.

Mr. Horn was the attorney with principal responsibility for prosecuting the case for the certified class of endpayers (health insurers and consumers) to recover overcharges paid for the prescription drug Hytrin. In re Terazosin Hydrochloide Antitrust Litigation, MDL 1317 (S.D. Fla.). The class action was settled for $29.3 million. Mr. Horn also had a lead role in litigating and settling, on behalf of WellPoint's subsidiary BCBS Wisconsin, and approximately 60 other health insurers, a substantial opt-out claim in the In re Lupron Marketing and Sales Practice Litigation, MDL 1430 (D.Mass.).

Mr. Horn frequently represents investors in commodities fraud litigations. He is currently co-lead counsel in In re Natural Gas Commodity Litigation, 03-cv-6186 (S.D.N.Y.), a case which concerns manipulation of New York Mercantile Exchange (“NYMEX”) Natural Gas futures contracts by multiple market participants through use of false trade reports to industry publications. Partial settlements, following certification of a three year class of NYMEX futures traders, of $72.6 million were approved by the Court in 2006. Mr. Horn also has helped achieve landmark results in the Sumitomo Copper Litigation, 182 F.R.D. 85 (S.D.N.Y. 1998) (a case involving manipulation of NYMEX copper futures which settled for more than $115 million) and In re Soybean Futures Litigation, 892 F.Supp. 1025 (N.D.Ill. 1995) (a case involving manipulation of Chicago Board of Trade soybean futures contracts which settled for more than $21 million).

Mr. Horn is a graduate of Trinity College (B.A. 1989) and Albany Law School (J.D. 1993). He is admitted to practice in New York, and the bars of the U.S.Court of Appeals for the 11th Circuit, and the U.S. District Court for the Southern District of New York.